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Abstract
Introduction: The aims of this study were fi rst, to determine whether peripheral levels of CD4+CD25highFoxp3+ 
regulatory T cells (Treg) are elevated in Prostate Cancer (PCa) patients, and second, to determine the direct 
correlation between peripheral Treg and total serum Prostate Specifi c Antigen (PSA) levels in these patients. 
Methods: Peripheral Blood Mononuclear Cells from 56 subjects undergoing diagnostic prostate biopsies 
(PSA ≥ 2.5 ng/ml) were analyzed for Treg numbers. The association between the peripheral Treg and serum 
PSA values was fi rst determined in the entire population, including people with no prostate pathology and 
PCa and Benign Prostate Hyperplasia (BPH) patients, and second, in nine PCa patients before and after 
curative prostatectomy. 
Results: This project was performed in Akdeniz University immunology laboratory and urology out patient 
clinic from 2008 to 2010. Peripheral Treg frequencies were signifi cantly increased in PCa patients (n = 19, 
3.23 ± 1.59) compared with BPH patients (n = 27, 1.66 ± 0.80) and healthy subjects (n = 10, 1.08 ± 0.43) 
(p < 0.01). The percentage of Treg in BPH patients was also signifi cantly higher than that of healthy subjects 
(p < 0.01). Importantly, the increase in BPH and PCa patients paralleled the elevation in total serum PSA 
levels, demonstrating a strong positive correlation (r = 0.75; p < 0.01).
Conclusion: These results demonstrate that peripheral Treg densities are correlated with PSA in BPH and 
PCa patients, suggesting that PSA may have a role in Treg induction and/or maintenance in Treg in these 
people. © 2011 All rights reserved
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Introduction
Prostate cancer (PCa) is the most commonly di-
agnosed cancer among men in the world (1). Ap-
proximately two thirds of PCa cases are confi ned 
to the prostate and can be treated by radical 
prostate removal or radiotherapy (2). In addition, 
approximately 25 to 55% of treated, locally con-
fi ned tumors reappear within 10 years and may 
progress as either a local recurrence or distant 
metastases (3). In the quest for eff ective preven-
tion and treatment modalities for metastatic 
PCa (4), immunotherapy attempts using several 
diff erent methods have shown very limited suc-
cess (5-9). Various immune evasion mechanisms, 
such as defects in antigen presentation, secretion 
of immunosuppressive agents by the tumor cells, 
and T cell receptor defects, are thought to limit 
the success of these trials. Recently, natural regu-
latory T cells (CD4+CD25high; Treg), one of the 
key regulators of self tolerance, have also been 
implicated in immune evasion by PCa (10, 11).
CD4+CD25high Treg cells, which are known to con-
trol self tolerance in the periphery, derive from 
the thymus (12, 13) and constitute 1-2% of pe-
ripheral lymphocytes in adult humans (14). Th e 
importance of these cells in tumor immunity was 
fi rst demonstrated three decades ago (15). Since 
then, especially aft er the introduction of Foxp3 
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(16) as a specifi c marker, stud-
ies of numerous mouse tumor 
models have demonstrated 
that they can interfere with the 
anti-tumor immune response 
at either the induction or ef-
fector phase. Increased periph-
eral and intratumoral Treg 
densities have been reported 
in lung, ovarian, colorectal, esophageal and gas-
tric, melanoma, head and neck, prostate and 
pancreatic cancers (17-20). Evidence for Treg in 
PCa patients, however, has been limited to a few 
recent studies with signifi cant controversy (21). 
Studies from experimental models have demon-
strated that Tregs may either be induced or ac-
tivated within the tumor draining lymph nodes 
by tumor-derived factors, including tumor-
associated antigens (TAA). Th en, these cells 
prevent tumor-specifi c immune responses ei-
ther at the induction phase in the tumor drain-
ing lymph nodes or at the eff ector phase within 
the tumor milieu (22, 23). Th e fi rst evidence 
that TAA-specifi c Tregs may be involved in sup-
pression of tumor-specifi c immune responses 
in humans has recently been reported (24).
Prostate-Specifi c Antigen (PSA), a serine pro-
tease produced by the prostate gland, is the best 
known TAA of the prostate. Large amounts of 
PSA are produced and released into circulation in 
PCa and BPH patients, as well as in people with 
prostate infl ammation. We demonstrate that the 
prevalence of Tregs is increased not only in PCa 
patients, but also in patients with BPH, and that 
this enhancement is strongly correlated with PSA, 
suggesting that PSA may have a role in Treg in-
duction and/or maintenance in these people. 
Th e varying results concerning peripheral Treg 
densities in PCa patients and the lack of infor-
mation regarding a correlation between PSA lev-
els and Treg cell frequency led us to investigate 
the number of peripheral CD4+CD25highFoxp3+ 
Tregs and their association with total serum PSA 
levels in PCa and BPH patients. Our results sup-
port that the frequency of Tregs increase not 
only in PCa patients, but also in BPH patients. 
Th is enhancement strongly correlates with PSA 
levels, suggesting a role for PSA in the Treg in-
duction and/or maintenance in these subjects.
Methods
Patients and Samples
Th is project was performed in Akdeniz Univer-
sity immunology laboratory and urology out 
patient clinic from 2008 to 2010. A total of 56 
patients with total serum PSA values of >2.5 ng/
ml, who were referred to transrectal ultrasound 
(TRUS)-guided sextant prostate biopsy at Ak-
deniz University Urology Outpatient Clinic, were 
recruited. Th e mean age of the patients was 62 
years (range 41 to 78 years). For Treg screen-
ing, 8 ml peripheral blood samples were drawn 
from patients into heparinized tubes just before 
the biopsy. None of the patients had any known 
current infections, and none were taking any im-
munomodulatory medications and none of them 
had any cancer before. Blood and biopsy samples 
were obtained with written consent under an 
institutional review board-approved protocol. 
 Of the total number of 56 patients that were ana-
lyzed, 19 were diagnosed with PCa, 27 with BPH and 
10 with no apparent prostate pathology (Table 1).
Of Of the 19 PCa patients, 17 had initial stage, lo-
cally confi ned cancer, while 2 had radiologically 
detected bony metastasis. Th e Gleason score was 
used to grade prostate cancer; where a high score is 
associated with advanced disease and poorer prog-
nosis. Of the 17 locally confi ned cancer patients, 
1 patient scored 5, 5 patients scored 6, 3 patients 
scored 7 and 10 patients scored 9. Of the 17 with 
locally confi ned PCa, 9 were treated by laparoscop-
ic radical prostatectomy at our hospital and were 
re-analyzed for both total serum PSA and periph-
eral Treg levels one month following the surgery.
10 who were negative for BPH, PCa and pros-
tatitis through pathological assessment were 
used as healthy controls. For Treg screen-
ing, 8 ml peripheral blood samples were drawn 
from patients into heparinized tubes just be-
fore the biopsy. Blood and biopsy samples 
Segment Healthy BPH PCa Total Subjects
Mean Age* 55 (43-68) 60 (44-70) 62 (41-78) 60 (43-78)
PSA* 3.3 (2.5-6) 20.4 (2.7-51) 45.4 (4.8-48) 25.3 (2.5-51)
Number 10 27 19 56
TABLE 1.  Summary of patient characteristics
*Numbers in parentheses show range
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were obtained with written consent under an 
institutional review board-approved protocol. 
Phenotypic and Quantitative Analysis of Lymphocytes:
Peripheral blood mononuclear cells (PBMCs) were 
isolated using a Fycoll-Hypaque density gradient. 
Surface staining with anti-human CD4-FITC (BD; 
555346), CD25-PE (BD; 555432) and intracellular 
staining with Foxp3-APC (e-Bioscience; 17-4776-
73) antibodies was performed as previously de-
scribed (22, 25). Briefl y, PBMCs were washed three 
times with D-PBS and stained for surface CD4 
and CD25 markers for 30 minutes at room tem-
perature. Finally, the cells were washed twice with 
saponin buff er and once with washing buff er and 
analyzed using a BD FACSCalibur Flow Cytometer. 
Flow-Jo soft ware (Tree Star Inc., San Carlos, CA) 
was used to analyze the samples and determine 
the frequencies of Treg cells. Absolute lymphocyte 
counts were determined by using an automated 
hematological analyzer (Sysmex XT-2000iV).
Serum PSA Quantifi cation: 
Total PSA (free + complexed) from serum sam-
ples was measured using an electrochemilumi-
nescence immunoassay (ECLIA) with a Roche 
Elecsys Modular Analytics E170 immunoassay 
analyzer according to manufacturer’s instructions. 
Statistical analysis 
All of the statistical analyses were performed using 
SPSS (version 16; SPSS Inc.). Statistical diff erences 
between groups were evaluated by using Krus-
kas-Wallis analysis. Th e diff erences between two 
groups were determined by the Mann-Whitney 
test with Benferroni Correction. Correlation was 
tested by the non-parametric Spearman method. 
Th e statistical signifi cance (p value) was set at <0.05.
Results
In this study, in order to avoid bias, we recruited 
patients with serum PSA values of >2.5 ng/ml 
(range 2.5-51) at the time of digital rectal exami-
nation and biopsy. Of the total number of 56 pa-
tients that were analyzed, 19 were diagnosed with 
PCa, 27 with BPH and 10 with no apparent pros-
tate pathology. Of the 19 cancer patients, 1 patient 
had a total Gleason score of 5.5 had a total Gleason 
score of 6.3 had a total Gleason score of 7 and 10 
had a total Gleason score of 9. Seventeen of the 
cancer patients had initial stage, locally confi ned 
cancer, while two had radiological detected bone 
metastasis. Ten people who were negative for BPH, 
PCa and prostatitis through pathological assess-
ment were used as healthy controls. Peripheral 
FIGURE 1.  (a) The gating strategy used for selecting 
CD25high cells was very stringent. (b) The mean frequencies of 
CD4+CD25highFoxp3+ Treg cells as percentages of peripheral 
lymphocytes were determined for PCa patients, BPH patients 
and healthy people, respectively.
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blood samples of all the patients at the time of bi-
opsy were analyzed by fl ow cytometry using CD4, 
CD25, Foxp3. Th e gating strategy used for select-
ing CD25high cells was very stringent (Figure 1a). 
Th e mean frequencies of CD4+CD25highFoxp3+ 
Treg cells as percentages of peripheral lympho-
cytes were determined as 3.23% ± 1.59% (n = 19), 
1.66% ± 0.80% (n = 27) and 1.08% ± 0.43%, (n = 
10) for PCa patients, BPH patients and healthy 
people, respectively (Figure 1b). Mean frequency 
of Tregs in PCa patients was signifi cantly higher 
than that of the BPH patients (p < 0.01) and healthy 
donors (p < 0.01). In addition, the mean frequen-
cy of Tregs in BPH patients was also signifi cantly 
higher than that of the healthy donors (p < 0.01). 
Finally, immunohis-
tochemical staining of 
prostate tissue sections 
from 19 PCa patients 
showed a substantial in-
crease in the number of 
Foxp3 expressing Treg in 
malignant tissue (Figure 
2b) compared with be-
nign tissue (Figure 2a). 
Th ere was a strong posi-
tive correlation between 
the two parameters 
with a correlation coef-
fi cient of 0.75 (p < 0.01). 
Nine PCa patients, 
who were treated 
by laparoscopic radical prostatectomy, were 
re-analyzed one-month post surgery for pe-
ripheral PSA and Treg levels (Figure 3).
Th e mean level of total serum PSA was 10.00 ± 
5.97 and the mean frequency of peripheral Treg 
was 3.20±1.61 before the surgery. Aft er curative 
prostatectomy, serum PSA levels of all the patients 
were reduced to very low/undetectable levels as 
expected [(0.20±0.49; paired t-test p < 0.01) (Fig-
ure 4a, b)]. Strikingly, the mean Treg frequencies 
in these patients also decreased signifi cantly [(1.09 
± 0.32; paired t-test p < 0.01) (Figure 4c, d)]. Th is 
result suggests that PSA alone or in combination 
with other tumor derived factors may be required 
for the increased presence of Treg in the periphery. 
In order to rule out a possible post-surgery 
stress eff ect on Treg frequencies, we recruited 
six more patients, in addition to our study group 
described above, that had previously planned 
to undergo non-PCa related prostate surger-
ies at our hospital. Th ese people were screened 
for Treg frequencies before and one month aft er 
the surgery. In these patients, the frequencies of 
Treg did not change signifi cantly aft er the surgery 
(1.11±0.20 to 1.13±0.22; paired t-test p > 0.05), 
demonstrating that surgery by itself does not 
cause a decrease in Treg frequency (Figure 4e, f).
Discussion
Th e purpose of this study was two-fold. First, we 
sought to verify whether the peripheral frequen-
cies of CD4+CD25highFoxp3+ Treg cells are elevated 
FIGURE 2.  (a) Low expressing Treg in Benign tissue (b) Substantial increase in the number 
of Foxp3 expressing Treg in malignant tissue in Pca patients.
FIGURE 3.  Correlation of serum PSA values with peripheral 
Treg frequencies
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in PCa patients; second, we aimed to determine 
the direct correlation between the peripheral 
Treg and total serum PSA levels in these patients. 
We fi rst demonstrated that CD4+CD25highFoxp3+ 
Treg densities are increased in PCa patients com-
pared with BPH patients and healthy controls. In 
addition to this observation, which is consistent 
with the fi ndings of Miller et al., (10) we also re-
corded a signifi cant enhancement in Treg frequen-
cy in the periphery of BPH patients compared 
with healthy controls. Even though Miller et al., 
(10) also clearly showed increased levels of Treg 
infi ltration in prostate tissue samples of BPH pa-
tients, these authors did not analyze those patients 
for peripheral Treg densities. Our results and 
those of Miller et al., however, contradict fi ndings 
of Yokokawa et al.(11), who observed no change in 
the frequencies of Treg cells in PCa patients except 
FIGURE 4.  (a) Treg frequencies of individual patients before and after the surgery. (b) Mean Treg frequencies (3.20 ± 1.61) 
were signifi cantly decreased after the surgery (1.09 ± 0.32). (c) Total serum PSA levels of individual patients before and after 
the surgery. (d) Mean serum PSA levels (10.00 ± 5.97) were signifi cantly decreased after the surgery (0.20 ± 0.49). (e) Treg 
frequencies of individual patients before and after non-PCa related surgery are shown. (f) Mean Treg frequencies (1.11 ± 0.20) 
were not signifi cantly changed after the non- PCa related surgery (1.13 ± 0.27).
80 JOURNAL OF HEALTH SCIENCES 2011; 1 (2)
YIGIT AKIN ET AL.: IS THERE ANY RELATIONSHIP BETWEEN PSA AND INCREASED PERIPHERAL CD4+CD25HIGHFOX3+ 
TREG IN PROSTATE CANCER PATIENTS?
in those with metastatic cancers. Seventeen of 19 
patients in the current study and all of the patients 
by Miller et al.(10) were reported to have locally 
confi ned cancer. Furthermore, despite the fact that 
the mean frequency of Tregs in PCa patients were 
comparable in all three studies, the mean frequen-
cy reported for healthy subjects by Yokokawa et 
al.(11) was considerably higher than the recorded 
results from our study as well as others, including 
Miller et al.(10) Th is discrepancy might have re-
sulted from the age of healthy controls used, which 
was 55 years (range 41-78 years) in our study.
Furthermore, our analysis clearly demonstrates 
that Tregs from PCa patients have signifi cant sup-
pressive activity. Secondly and more importantly, 
we demonstrate for the fi rst time that a strong as-
sociation exists between the high density of Tregs 
and total serum PSA in both BPH and PCa patients, 
suggesting that the increased frequency of Tregs 
may not be a result of malignity, but may rather be 
caused by the excessive amounts of PSA accumula-
tion in these patients. We obtained the fi rst line of 
evidence for this assumption during the diagnos-
tic process, by showing that Treg frequencies were 
strongly correlated with serum PSA in patients 
with serum PSA levels of 2.5-51 ng/ml, regardless 
of the disease status (r = 0.75, p < 0.05). Th e evi-
dence for the strong association of PSA with Tregs 
was obtained from the analysis of nine patients 
with locally confi ned cancers, who were treated by 
radical prostatectomy. Treg frequencies of all these 
patients subsided remarkably one month follow-
ing surgery. Interestingly, although three of these 
patients had Treg levels near the threshold Treg 
frequency of 2.1% (95% CI), these levels further 
declined. Th is suggests that tumor-specifi c Tregs 
might still exist and be depleted upon antigen re-
moval, even in patients whose Treg levels are not 
elevated. Our result is in agreement with Kono et 
al. (30), who have recently observed a similar re-
duction of peripheral Treg levels in gastric cancer 
patients that underwent curative surgeries. Taken 
together, our results strongly suggest that PSA, ei-
ther alone or with other prostate derived factors, 
is involved in either the induction and/or mainte-
nance of peripheral Tregs in BPH and PCa patients.
Th is study was limited by patients number, be-
cause our clinic is not a urologic cancer clinic.
Th e reason for the enhanced number of Tregs 
in human cancers is not clear. It is hypothesized 
that TAA in the presence of soluble mediators, 
such as TGF-β and chemokines may be required 
for peripheral induction and/or expansion of 
Tregs within the tumor-draining lymph nodes. 
We also do not know whether other factors, ei-
ther tumor-derived or tumor-induced, are also 
required in these processes. Previous in vitro 
studies demonstrated that PSA is able to induce 
TGF-β production and impair dendritic cell matu-
ration. Both of these pathways are known to in-
duce Tregs, in vivo in experimental models and 
in vitro in human PBMC cultures and thus, it is 
reasonable to assume that excessive amounts of 
PSA in both BPH and PCa patients may invoke 
one or both of the above pathways to either in-
duce or expand PSA-specifi c Tregs. It is also likely 
that other mechanisms, such as IDO (Indoleamin 
2-3 deoxygenase) or PGE-2 production by the 
cells within the tumor milieu might contribute 
to the process. Further studies addressing these 
questions will be important for our understand-
ing of the biology of the Treg in human cancer. 
Restoring peripheral Treg levels upon removal of 
cancerous prostates also has important implications 
for immunotherapy for PCa. Many prostate-specif-
ic vaccine trials using PSA peptides to stimulate tu-
mor-specifi c immune responses before the surgical 
removal of tumors have not yielded desired results. 
Conclusions
In this study we present, to our knowledge, the 
fi rst evidence in the literature that increased 
frequency of circulating CD4+CD25highFoxp3+ 
Tregs in PCa and BPH patients is correlated 
with PSA levels and also the fi rst to demon-
strate a strong dynamic association between 
a TAA and Tregs in cancer bearing humans.
 Our results demonstrate that peripheral Treg den-
sities are correlated with PSA in BPH and PCa 
patients, suggesting that PSA may have a role in 
Treg induction and/or maintenance in Treg in 
these people. In the light of these fi ndings, we 
may expect better response of treatment of tu-
mour specifi c immunotherapy aft er removal of 
prostate gland which includes adenocarcinoma 
cells. More comprehensive studies on this issue by 
holding the light of fi ndings in immunotherapy 
for PCa may provide new forms of treatments.
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